

AbbVie Inc.  
Form 8-A12B  
November 17, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-A**

**FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES  
PURSUANT TO SECTION 12(b) OR (g) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**ABBVIE INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of incorporation or  
organization)

**32-0375147**  
(I.R.S. Employer Identification No.)

**1 North Waukegan Road**  
**North Chicago, Illinois**  
(Address of principal executive offices)

**60064-6400**  
(Zip Code)

Securities to be registered pursuant to Section 12(b) of the Act:

**Title of each class  
to be so registered**  
**0.375% Senior Notes due 2019**  
**1.375% Senior Notes due 2024**  
**2.125% Senior Notes due 2028**

**Name of each exchange on which  
each class is to be registered**  
**New York Stock Exchange**  
**New York Stock Exchange**  
**New York Stock Exchange**

Edgar Filing: AbbVie Inc. - Form 8-A12B

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box.  X

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box.  O

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box.  O

Securities Act registration statement or Regulation A offering statement file number to which this form relates: **333-203677**

Securities to be registered pursuant to Section 12(g) of the Act: **None**

---

**Item 1. Description of Registrant's Securities to be Registered.**

The securities to be registered hereunder are 1,400,000,000 aggregate principal amount of 0.375% Senior Notes due 2019, 1,450,000,000 aggregate principal amount of 1.375% Senior Notes due 2024 and 750,000,000 aggregate principal amount of 2.125% Senior Notes due 2028 (collectively, the Notes) of AbbVie Inc., a Delaware corporation (the Registrant). Descriptions of the general terms and provisions of the Notes are set forth under the caption "Description of Debt Securities" in the prospectus dated April 27, 2015, included in the Registrant's registration statement on Form S-3ASR (File No. 333-203677) filed with the Securities and Exchange Commission on April 27, 2015, and under the caption "Description of Notes" in the prospectus supplement thereto dated November 14, 2016, which was filed with the Securities and Exchange Commission on November 16, 2016 pursuant to Rule 424(b) under the Securities Act of 1933, as amended, and are incorporated by reference herein.

**Item 2. Exhibits.**

A list of exhibits incorporated by reference in this registration statement on Form 8-A immediately follows the signature page of this registration statement on Form 8-A and is incorporated herein by reference.

**SIGNATURE**

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

**ABBVIE INC.**

Date: November 17, 2016

By:	/s/ Robert A. Michael	
Name:		Robert A. Michael
Title:		Vice President, Treasurer

**Exhibit Index**

<b>Exhibit Number</b>	<b>Description</b>
4.1	Indenture, dated as of November 8, 2012, between AbbVie Inc. and U.S. Bank National Association, as trustee (incorporated by reference to Exhibit 4.1 of Amendment No. 5 to AbbVie Inc.'s Registration Statement on Form 10 filed on November 16, 2012).
4.2	Supplemental Indenture No. 4, dated November 17, 2016, among AbbVie Inc. and U.S. Bank National Association, as trustee, Elavon Financial Services DAC, U.K. Branch, as paying agent and Elavon Financial Services DAC, as transfer agent and registrar (including the forms of Global Notes attached as Exhibits A-1, A-2 and A-3 to the Supplemental Indenture No. 4) (incorporated by reference to Exhibit No. 4.1 to the Registrant's Current Report on Form 8-K filed on November 17, 2016).
4.3	Agency Agreement, dated November 17, 2016, among AbbVie Inc., U.S. Bank National Association, as trustee, Elavon Financial Services DAC, U.K. Branch, as paying agent and Elavon Financial Services DAC, as transfer agent and registrar (incorporated by reference to Exhibit 4.2 to the Registrant's Current Report on Form 8-K filed on November 17, 2016).